Skip to main content
SpringerLink
Log in

Future of Coronary Thrombolysis

  • Chapter
The Modern Era of Coronary Thrombolysis

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 160))

  • 59 Accesses

Abstract

Despite its now established efficacy, the evolution of coronary thrombolysis has been protracted. Delay in its acceptance after initial attempts in 1958 (1) resulted from the initial lack of optimal end points such as coronary arteriography and the “mind set” in the cardiovascular community that did not favor thrombosis as the proximate cause of acute myocardial infarction and that did not recognize the dependence of benefit from coronary recanalization on the brevity of antecedent ischemia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fletcher AP, Sherry S, Alkj aersig N, Smyrniotis FE, Jick S: The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest 1959;38:1111–1119

    Article  PubMed  CAS  Google Scholar 

  2. Sones FM, Jr., Shirey EK, Proudfit WL, Wescott RN: Cine arteriography. Circulation 1959;20:773–774

    Google Scholar 

  3. Maseri A, L’Abbate A, Baroldi G, et al: Coronary vasospasm as a possible cause of myocardial infarction. A conclusion derived from the study of “preinfarction” angina. N Engl J Med 1978;299:1271–1277

    Article  PubMed  CAS  Google Scholar 

  4. Tiefenbrunn AJ, Sobel BE: Factors contributing to the emergence of coronary thrombolysis. Cardiol Clin 1987;5:49–53

    PubMed  CAS  Google Scholar 

  5. Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J, Jr., Braunwald E: Factors influencing infarct size following experimental coronary artery occlusions. Circulation 1971;43:67–82

    Article  PubMed  CAS  Google Scholar 

  6. Chazov EI, Matveeva LS, Mazaev AV, Sargin KE, Sadovskaia GV, Ruda MI: Intracoronary administration of fibrinolysis in acute myocardial infarction. Ter-Arkh 1976;48:8–19

    PubMed  CAS  Google Scholar 

  7. Rentrop KP, Blanke H, Karsch KR, et al: Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 1979;2:354–363

    PubMed  CAS  Google Scholar 

  8. Gruppo Italiano Per Lo Studio Delia Streptochinasi Nell’infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397–401

    Google Scholar 

  9. van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KAA, de Geest H, Verstraete M, Collen D, Sobel BE: Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med 1984;310:609–613

    Article  PubMed  Google Scholar 

  10. Sobel BE: Safety and efficacy of tissue-type plasminogen activator produced by recombinant DNA technology (rt-PA). J Am Coll Cardiol 1987;10:40B–44B

    Article  PubMed  CAS  Google Scholar 

  11. Chesebro JH, Knatterud G, Roberts R, Borer J, et al for the TIMI Investigators: Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987;76:142–154

    Article  PubMed  CAS  Google Scholar 

  12. Gruppo Italiano Per Lo Studio Delia Sopravvivenza Nell’ infarto Miocardico: GISSI 2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65–71

    Google Scholar 

  13. ISIS-3: A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753–770

    Article  Google Scholar 

  14. Sobel BE, Collen D: Questions unresolved by the Third International Study of Infarct Survival. Am J Cardiol 1992;70:385–389

    Article  PubMed  CAS  Google Scholar 

  15. Tiefenbrunn AJ, Sobel BE: Timing of coronary recanalization. Paradigms, paradoxes, and pertinence. Circulation 1992;85:2311–2315

    Article  PubMed  CAS  Google Scholar 

  16. Sobel BE, Hirsh J: Principles and practice of coronary thrombolysis and conjunctive treatment. Am J Cardiol 1991;68:382–388

    Article  PubMed  CAS  Google Scholar 

  17. Eisenberg PR, Sherman L, Rich M, et al: Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986;7:1255–1262

    Article  PubMed  CAS  Google Scholar 

  18. Hopkins WE, Fujii S, Sobel BE: Synergistic induction of plasminogen activator inhibitor type-1 in Hep G2 cells by thrombin and transforming growth factor. Blood 1992;79:75–81

    PubMed  CAS  Google Scholar 

  19. Fujii S, Sobel BE: Determinants of induction of increased synthesis of plasminogen activator inhibitor type-1 in human endothelial cells by t-PA. Thromb Haemost 1992;67:233–238

    PubMed  CAS  Google Scholar 

  20. Fujii S, Hopkins WE, Sobel BE: Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type-2 in endothelial cells by constituents of platelets and their implications for thrombolysis. Circulation 1991;83:645–651

    Article  PubMed  CAS  Google Scholar 

  21. Sobel BE: Insulin, thrombosis, and coronary artery disease, in Pitt B (ed): Mechanisms of Coronary Disease. New York, Cahners Healthcare Communications, 1992, pp 28–33

    Google Scholar 

  22. Torr SR, Nachowiak DA, Fujii S, Sobel BE: “Plasminogen steal” and clot lysis. J Am Coll Cardiol 1992;19:1085–1090

    Article  PubMed  CAS  Google Scholar 

  23. Onundarson PT, Francis CW, Marder VJ: Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential. J Lab Clin Med 1992;120:120–128

    PubMed  CAS  Google Scholar 

  24. Weaver WD: Myocardial Infarction Triage and Intervention (MITI) trial of prehospital initiated thrombolysis-results. Presented at the American College of Cardiology National Meeting, Dallas, April 14, 1992

    Google Scholar 

  25. Blankenhom DH: Angiographic trials of cholesterol lowering in patients with atherosclerosis: an overview. Cholesterol and Coronary Disease... Reducing the Risk 1993;3:4–7

    Google Scholar 

  26. Fujii S, Sawa H, Saffitz JE, Lucore CL, Sobel BE: Induction of endothelial cell gene expression of plasminogen activator inhibitor type-1 (PAI-1) by thrombosis in vivo. Circulation 1992;86:2000–2010

    Article  PubMed  CAS  Google Scholar 

  27. Fujii S, Sobel BE: Direct effects of gemfibrozil on the fibrinolytic system. Circulation 1992;85:1888–1893

    Article  PubMed  CAS  Google Scholar 

  28. Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A: Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989;79:980–989

    Article  PubMed  CAS  Google Scholar 

  29. Tebbe U, Massberg I, Windeier J, Barth H, LIMITS-Studiengruppe: Einfluss von heparin auf die thrombolytische Wirksamkeit van saruplase beim akuten myockardinfarkt. Z Kardiol 1991;80(suppl 3):32 (Abstract)

    Google Scholar 

  30. Collen D, De Cock F, Vanlinthout I, Declerck PJ, Lijnen HR, Stassen JM: Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis 1992;6:232–242

    CAS  Google Scholar 

  31. Sobel BE, Sarnoff SJ, Nachowiak DA: Augmented and sustained plasma concentrations after intramuscular injections of molecular variants and deglycosylated forms of tissue-type plasminogen activators. Circulation 1990;81:1362–1373

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division and Center for Cardiovascular Research, Washington University School of Medicine, USA

    Burton E. Sobel M.D.

Authors
  1. Burton E. Sobel M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Thrombosis Research Center, University of Massachusetts Medical Center, Worcester, Massachusetts, USA

    Richard C. Becker M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sobel, B.E. (1994). Future of Coronary Thrombolysis. In: Becker, R.C. (eds) The Modern Era of Coronary Thrombolysis. Developments in Cardiovascular Medicine, vol 160. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2618-6_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2618-6_19

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6122-0

  • Online ISBN: 978-1-4615-2618-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation